Dr. Alice Chen has been a vice president at ALSP since 2017. She initially joined ALSP in 2013 as a principal to support portfolio company operations and to provide executive oversight of preclinical development activities across the portfolio. She is actively involved in sourcing and scientifically evaluating emerging biotechnology investment opportunities and has played an instrumental role in the formation and oversight of several ALSP portfolio companies, including Acylin Therapeutics, Nemean Pharma, Rodeo Therapeutics and Magnolia Neurosciences.
Dr. Chen has more than 15 years of research and drug development experience, principally in small molecule therapeutics. Before joining ALSP, she served as a scientific consultant and drug development project leader for several venture-backed biotechnology companies. Prior to that, she served as Director of Technologies at Qwell Pharmaceuticals, a venture-backed biotechnology company developing novel, small-molecule drugs focused on cancer and inflammation. She also contributed to partnership and M&A initiatives.
Dr. Chen completed her doctoral training in the laboratory of Dr. Chaitan Khosla at Stanford University where she focused on protein engineering and protein characterization. She holds a Ph.D. in Chemical Engineering from Stanford University and a B.S. degree in Chemical Engineering from U.C. Berkeley. She served as an Engineering Fellow at Merck & Company and is a graduate of the Kauffman Fellows Program (Class 19). Dr. Chen currently serves on the boards of the Evergreen Fund Advisory Committee for the Fred Hutch Cancer Research Center and Life Science Washington, the state’s life science trade association.